Roxatidine

Intravenous
Upper gastrointestinal haemorrhage

Oral
Zollinger-Ellison syndrome

Oral
Gastro-oesophageal reflux disease

Oral
Premedication before anaesthesia

Oral
Peptic ulcer

Oral
Gastritis

Oral:
Zollinger-Ellison syndrome:

CrCl	Dosage
<20	75 mg every 2 days.
20-50	75 mg at bedtime.

Gastro-oesophageal reflux disease:

CrCl	Dosage
<20	75 mg every 2 days.
20-50	75 mg at bedtime.

Peptic ulcer:

CrCl	Dosage
<20	75 mg every 2 days.
20-50	75 mg at bedtime.

Gastritis:

CrCl	Dosage
<20	75 mg every 2 days.
20-50	75 mg at bedtime.

Lactation. Porphyria.

Renal and hepatic impairment, pregnancy. May mask the symptoms of gastric malignancy.

Occasional headache, GI disturbances, gynaecomastia, alopecia, blood dyscrasias, pancreatitis, sleep disturbances, restlessness, rarely dizziness. Hypersensitivity reactions e.g. rash and itching reported occasionally. Changes in pulse rate and transient impairment of sexual drive. Possible increase in liver enzyme activity. May reduce leucocytes and/or thrombocytes.

May affect serum levels of protease inhibitors.

Description: Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H₂-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action.
Pharmacokinetics:
Absorption: Absorbed rapidly and almost completely from the GI tract (oral); peak plasma concentrations after 1-3 hr.
Distribution: Enters breast milk (small amounts).
Metabolism: Liver, small intestines and serum; hydrolysed to the desacetyl metabolite.
Excretion: Via urine (90% as roxatidine and metabolites); 6 hr (elimination half-life).

Antacids, Antireflux Agents & Antiulcerants